206 related articles for article (PubMed ID: 29855498)
1. BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells.
Biswas S; Li P; Wu H; Shafiquzzaman M; Murakami S; Schneider MD; Mishina Y; Li B; Li J
Sci Rep; 2018 May; 8(1):8475. PubMed ID: 29855498
[TBL] [Abstract][Full Text] [Related]
2. p38α MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions.
Cong Q; Jia H; Biswas S; Li P; Qiu S; Deng Q; Guo X; Ma G; Ling Chau JF; Wang Y; Zhang ZL; Jiang X; Liu H; Li B
Stem Cell Reports; 2016 Apr; 6(4):566-578. PubMed ID: 26947973
[TBL] [Abstract][Full Text] [Related]
3. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.
Kamiya N; Ye L; Kobayashi T; Lucas DJ; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
J Bone Miner Res; 2008 Dec; 23(12):2007-17. PubMed ID: 18684091
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminases factor XIII-A and TG2 regulate resorption, adipogenesis and plasma fibronectin homeostasis in bone and bone marrow.
Mousa A; Cui C; Song A; Myneni VD; Sun H; Li JJ; Murshed M; Melino G; Kaartinen MT
Cell Death Differ; 2017 May; 24(5):844-854. PubMed ID: 28387755
[TBL] [Abstract][Full Text] [Related]
5. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
[TBL] [Abstract][Full Text] [Related]
7. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
8. Inhibin α-subunit inhibits BMP9-induced osteogenic differentiation through blocking BMP/Smad signal and activating NF-κB signal in mesenchymal stem cells.
Huang M; Cheng YL; Zeng JT; Su XY; Liu H
J Cell Biochem; 2018 Nov; 119(10):8271-8281. PubMed ID: 29923343
[TBL] [Abstract][Full Text] [Related]
9. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass.
Kamiya N; Atsawasuwan P; Joiner DM; Waldorff EI; Goldstein S; Yamauchi M; Mishina Y
Bone; 2020 Sep; 138():115513. PubMed ID: 32603910
[TBL] [Abstract][Full Text] [Related]
10. Ginkgo biloba extract promotes osteogenic differentiation of human bone marrow mesenchymal stem cells in a pathway involving Wnt/β-catenin signaling.
Gu Q; Chen C; Zhang Z; Wu Z; Fan X; Zhang Z; Di W; Shi L
Pharmacol Res; 2015 Jul; 97():70-8. PubMed ID: 25917209
[TBL] [Abstract][Full Text] [Related]
11. Deletion of BMP receptor type IB decreased bone mass in association with compromised osteoblastic differentiation of bone marrow mesenchymal progenitors.
Shi C; Iura A; Terajima M; Liu F; Lyons K; Pan H; Zhang H; Yamauchi M; Mishina Y; Sun H
Sci Rep; 2016 Apr; 6():24256. PubMed ID: 27048979
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
13. The mammalian lectin galectin-8 induces RANKL expression, osteoclastogenesis, and bone mass reduction in mice.
Vinik Y; Shatz-Azoulay H; Vivanti A; Hever N; Levy Y; Karmona R; Brumfeld V; Baraghithy S; Attar-Lamdar M; Boura-Halfon S; Bab I; Zick Y
Elife; 2015 May; 4():e05914. PubMed ID: 25955862
[TBL] [Abstract][Full Text] [Related]
14. Effect of TAK1 on osteogenic differentiation of mesenchymal stem cells by regulating BMP-2 via Wnt/β-catenin and MAPK pathway.
Yang H; Guo Y; Wang D; Yang X; Ha C
Organogenesis; 2018 Jan; 14(1):36-45. PubMed ID: 29913119
[TBL] [Abstract][Full Text] [Related]
15. Altered plasma membrane dynamics of bone morphogenetic protein receptor type Ia in a low bone mass mouse model.
Bragdon B; D'Angelo A; Gurski L; Bonor J; Schultz KL; Beamer WG; Rosen CJ; Nohe A
Bone; 2012 Jan; 50(1):189-99. PubMed ID: 22036911
[TBL] [Abstract][Full Text] [Related]
16. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice.
Okamoto M; Murai J; Imai Y; Ikegami D; Kamiya N; Kato S; Mishina Y; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2011 Oct; 26(10):2511-22. PubMed ID: 21786321
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling.
Mishina Y; Starbuck MW; Gentile MA; Fukuda T; Kasparcova V; Seedor JG; Hanks MC; Amling M; Pinero GJ; Harada S; Behringer RR
J Biol Chem; 2004 Jun; 279(26):27560-6. PubMed ID: 15090551
[TBL] [Abstract][Full Text] [Related]
18. Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice.
Qi B; Cong Q; Li P; Ma G; Guo X; Yeh J; Xie M; Schneider MD; Liu H; Li B
Sci Rep; 2014 Nov; 4():7158. PubMed ID: 25418008
[TBL] [Abstract][Full Text] [Related]
19. Synergy between IL-6 and soluble IL-6 receptor enhances bone morphogenetic protein-2/absorbable collagen sponge-induced bone regeneration via regulation of BMPRIA distribution and degradation.
Huang RL; Chen G; Wang W; Herller T; Xie Y; Gu B; Li Q
Biomaterials; 2015 Oct; 67():308-22. PubMed ID: 26232880
[TBL] [Abstract][Full Text] [Related]
20. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
